Multimodal treatment of esophageal cancer |
| |
Authors: | Florian Lordick Arnulf H. Hölscher Karen Haustermans Christian Wittekind |
| |
Affiliation: | 1. University Cancer Center Leipzig (UCCL), University Clinic Leipzig, Liebigstra?e 20, 04103, Leipzig, Germany 2. Department of General Visceral and Cancer Surgery, University of Cologne, Cologne, Germany 3. Department of Radiation Oncology, Catholic University of Leuven, Louvain, Belgium 4. Institute of Pathology, University Clinic Leipzig, Leipzig, Germany
|
| |
Abstract: | ![]()
Background The treatment of localized esophageal cancer has been debated controversially over the past decades. Neoadjuvant treatment was used empirically, but evidence was limited due to the lack of high-quality confirmatory studies. Meanwhile, data have become much clearer due to recently published well-conducted randomized controlled trials and meta-analyses. Methods Neoadjuvant and perioperative platinum fluoropyrimidine-based combination chemotherapy has now an established role in the treatment of stage II and stage III esophageal adenocarcinoma and cancer of the esophago-gastric junction. Neoadjuvant chemoradiation is now the standard of care for treating stage II and stage III esophageal squamous cell cancer and can also be considered for treating esophageal adenocarcinoma. Results Patients with esophageal squamous cell cancer treated with definitive chemoradiation achieve comparable long-term survival compared with surgery. Short-term mortality is less with chemoradiation alone, but local tumor control is significantly better with surgery. Conclusion This expert review article outlines current data and literature and delineates recommendable treatment guidelines for localized esophageal cancer. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|